Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORION-1 PREVENT: inclisiran for primary prevention of major cardiovascular events in high-risk patients
CTR20231501Phase 3Active
- Sponsor
- Novartis
- Start
- Aug 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of inclisiran in atherosclerotic disease, sponsored by Novartis. Started Aug 2023; status: active.
02
Drugs
inclisiran
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on CTR20231501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231501.